Navigation Links
Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting

SAN DIEGO, May 21, 2007 /PRNewswire/ -- Asenapine -- an investigational drug being developed by Organon, the human healthcare business unit of Akzo Nobel, for bipolar I disorder and schizophrenia -- was demonstrated to be more effective than placebo in treating acute manic and mixed episodes associated with bipolar I disorder, according to new Phase III results, from a study presented at the American Psychiatric Association's 2007 Annual Meeting.

In the three-week study, patients treated with either asenapine or olanzapine experienced significant improvements in acute mania symptoms, versus patients given placebo. Both asenapine and olanzapine demonstrated superiority versus placebo by the second day of treatment and maintained this benefit throughout the trial.

"The consequences of untreated mania in patients with bipolar disorder can be devastating to patients and their families. We need more effective and more tolerable treatments for these patients," said Robert Hirschfeld, M.D., Professor and Chair of the Department of Psychiatry and Behavioral Sciences at The University of Texas Medical Branch, Galveston. "The results of this trial suggest that asenapine is an attractive option for the acute treatment of mania because of its rapid onset of action and modest side effect profile."

Phase III Study Overview

The Phase III, double-blind, international trial conducted at 55 centers including 29 sites in the United States enrolled 488 patients with a manic (69%) or a mixed episode (31%) of bipolar I disorder and a baseline Young Mania Rating Scale (YMRS) score greater than or equal to 20 at entry. The YMRS is an 11-item scale used to evaluate manic symptoms; a score of at least 20 represents moderate-to-severe mania. Patients were randomly treated with asenapine (5-10 mg twice daily; average daily dose, 18.2 mg), olanzapine (5-20 mg once daily; average daily dose, 15.8 mg), or placebo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
2. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
5. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
6. Gabapentin Shown Effective for Fibromyalgia Pain
7. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
8. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
9. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
10. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
11. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
Post Your Comments:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... Company announces the recent formation of Alamo ... wholly owned subsidiary of Mission, will provide ... resources (HR) support.  Alamo will be headquartered ... States presence, which also includes the company,s ...
... Jan. 26, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc.- Florida has reached a settlement with ... Watson,s generic versions of Mallinckrodt,s Exalgo® (Hydromorphone Hydrochloride ... December 10, 2010 in the United States District ...
Cached Medicine Technology:Mission Pharmacal Launches Alamo Pharma Services 2Mission Pharmacal Launches Alamo Pharma Services 3Watson Reaches Settlement with Mallinckrodt Over Exalgo(R) 2
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... reveals racial disparities, troublesome drug side effects , , THURSDAY, ... first annual Breast Cancer Symposium shed light on racial ... can affect survival, and how nagging side effects cause ... in San Francisco, is co-sponsored by the American Society ...
... Stars, Nation,s ... Sept. 6 Consumer,selection of foods that offer more ... don,t in many aisles of Hannaford Supermarkets --,in some ... data in the year,since the company launched Guiding Stars, ...
... Mylan Laboratories Inc.,(NYSE: MYL ) today announced that ... Food and Drug Administration for its,Abbreviated New Drug Application ... and 25 mg. Carvedilol Tablets are the generic ... of approximately $1.65,billion for the 12 months ending June ...
... N.Y., Sept. 5 Fairbank Farms, a national,ground ... Lean Ground Round Beef Patties. The ground beef ... been purchased by consumers in New,England on Wednesday ... of an abundance of caution, the product has ...
... starved environments have been used successfully to target ... according to scientists speaking today (Thursday 6 September ... Meeting at the University of Edinburgh, UK, which ... half of cancer sufferers our traditional treatments such ...
... Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... the product will commence,immediately. Carvedilol tablets, ... be available in 3.125, 6.25, 12.5 and ...
Cached Medicine News:Health News:Studies Shed New Light on Breast Cancer, Treatment 2Health News:Studies Shed New Light on Breast Cancer, Treatment 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4Health News:Bacteria successful in cancer treatment 2Health News:Actavis Launches Carvedilol Tablets in the U.S. 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Acuity Meter (RAM) is the first visual examination ... RETINAL ACUITY in eyes with glaucoma, cataract, and ... and can test each eye easily in under ... tested at Columbia University in New York City, ...
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
... Ace Align is an external fixator designed ... of the femur, tibia, humerus and forearm. ... where external fixation is the treatment of ... ,The Ace Align is fully compatible with ...
Medicine Products: